FDA approves once-monthly injection for opioid addiction

December 4, 2017

(HealthDay)—Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

Buprenorphine has been shown to reduce opioid withdrawal symptoms and the desire to use opioids, "without causing the cycle of highs and lows associated with or abuse," the FDA said.

Sublocade was evaluated in involving 848 adults who were diagnosed with moderate-to-severe cases of opioid use disorder. The most common side effects included constipation, nausea, vomiting, headache, drowsiness, and injection-site pain. Sublocade's safety and effectiveness were not evaluated in individuals under age 17, the FDA said.

The maker of Sublocade—Indivior—is required to conduct additional studies to see if some patients could benefit from a dose of Sublocade that's higher than currently approved.

Indivior is based in the United Kingdom.

Explore further: Clinical trial looks at tramadol for opioid withdrawal

More information: More Information

Related Stories

Clinical trial looks at tramadol for opioid withdrawal

July 12, 2017
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential ...

Injectable therapy blocks opioid euphoria, withdrawal symptoms in trial

June 26, 2017
A study led by investigators in the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated a weekly injectable formulation of buprenorphine, CAM2038, suppresses symptoms of withdrawal in patients ...

Movantik approved for constipation from opioids

September 16, 2014
(HealthDay)—Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.

Gabapentin co-use may increase risk of fatal opioid overdose

October 3, 2017
Co-prescription of the anticonvulsant gabapentin is associated with an increased risk of opioid-related death in people who are prescribed opioid painkillers, according to a new study published in PLOS Medicine.

FDA asks maker of opioid painkiller opana ER to pull drug from market

June 9, 2017
(HealthDay)—Sales of reformulated Opana ER, a prescription opioid painkiller, should be halted in the United States, the U.S. Food and Drug Administration says.

Why are doctors underusing a drug to treat opioid addiction?

August 3, 2017
A drug approved for private physicians to treat opioid addiction is being underprescribed, and a survey of addiction specialists suggests that many of them are not willing to increase their use of it, despite an expanding ...

Recommended for you

Discovery opens door for synthetic opioids with less addictive qualities

June 1, 2018
Making opioids from sugar instead of from field grown opium poppies has the potential to solve many of the problems associated with manufacturing strong pain killers.

US doctors prescribing fewer opioid painkillers: report

May 31, 2018
US doctors reduced the number of prescriptions for opioid painkillers last year, continuing a five-year trend, in an effort to reverse a deadly drug abuse epidemic, a report released Thursday said.

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.